NASDAQ:RNAC
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc.'s revenue fell 92.8% in fiscal 2025 to $2.8M while operating margin fell to −5127.1%. Free cash flow was −$79.4M, −2838.6% of revenue, and the diluted share count rose 49.6%.Summary generated from Cartesian Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.8M
Revenue growth−92.8%
Revenue, 5-yr CAGR−30.0%
Gross marginn/a
Operating margin−5127.1%
Net margin−4658.6%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$79.4M
FCF margin−2838.6%
Share count change+49.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 85 | 111 | 26 | 39 | 3 |
| Operating income | −5 | 15 | −86 | −44 | −143 |
| Net income | −26 | 35 | −220 | −77 | −130 |
| Free cash flow | −61 | −33 | −51 | −33 | −79 |
Recent filings
- 8-KRegulation FD disclosure
Sep 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KResults of a shareholder vote
Jun 17, 2026 - 8-KRegulation FD disclosure
Jun 9, 2026 - 8-KEntry into a material agreement
May 26, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026 - 8-KResults of operations and financial condition
Apr 30, 2026